PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-08-castro.pdf
Related image for press use: http://www.plos.org/press/plme-03-08-castro.jpg
Caption: Annual Treatment Cost of Stavudine (d4T) 40mg + Lamivudine (3TC) 150mg + Nevirapine (NVP) 200mg Per Patient in Countries Receiving PEPFAR Funding For Which Cost Information Is Available. Source: Global Price Reporting Mechanism, http://www.who.int/3by5/amds/price/hdd/index.aspx
Note: The calculations have been made with the most recent cost published. Drug manufacturers include Cipla (FDC), Bristol-Myers Squibb (d4T), GlaxoSmithKline (3TC), and Boehringer Ingelheim (NVP). In all these countries, the annual cost of branded d4T is US$55 and that of branded 3TC is US$70; NVP accounts for the rest of the cost.
CONTACT:
Arachu Castro
Harvard Medical School
Program in Infectious Disease and Social Change, Department of Social Medicine
641 Huntington Avenue
Boston, MA 02115 United States of America
1-617-432-6038
1-617-432-6045 (fax)
Arachu_Castro@hms.harvard.edu
Improving the survival of newborn infants in the slums of Mumbai
In India, 26 million babies are born every year, and 1.2 million die in the first four weeks of life, a figure that accounts for a quarter of global neonatal deaths. India thus faces the biggest newborn health challenge of any country in the world. Researchers from Mumbai and London describe an innovative project, The City Initiative for Newborn Health, aimed at improving the survival and health of mothers and newborn infant
'"/>
Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
7-Aug-2006
